JAK2 V617F Mutation Analysis
Use
This assay determines JAK2 V617F mutation status. The JAK2 V617 mutation is found in 65-97% of patients with polycythemia vera (PV), 23-57% with essential thrombocythemia (ET), and 43-50% with idiopathic myelofibrosis. It aids in the diagnosis of these chronic myeloproliferative disorders.
Special Instructions
Frozen blood and bone marrow samples are NOT accepted. Isolation of nucleic acids for clinical testing must occur in a CLIA-certified laboratory or a laboratory meeting equivalent requirements. Concentration and volume must be provided for all samples.
Limitations
This test is for Research Use Only (RUO) and is not intended for clinical diagnosis. Improper specimen labeling, insufficient sample volume, clotted specimens, or specimens beyond stability may lead to rejection. Insufficient DNA isolated is also a cause for rejection.
Methodology
PCR-based (RT-PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5mL
Minimum Volume
3mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimens beyond stability; Insufficient DNA isolated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 30 days |
| Frozen | Long Term |